Cargando…

Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis

Detalles Bibliográficos
Autor principal:	Yoon, Hyuk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667369/ https://www.ncbi.nlm.nih.gov/pubmed/31352773 http://dx.doi.org/10.5217/ir.2019.00070

Ejemplares similares

Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
por: Kim, Jae Hyun, et al.
Publicado: (2016)

Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
por: Schultz, Bob G, et al.
Publicado: (2021)

Is Long-Term Therapy With Thiopurines Effective for Maintaining Remission in Patients With Moderate-To-Severe Ulcerative Colitis?
por: Jeon, Seong Ran, et al.
Publicado: (2015)

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
por: Kobayashi, Taku, et al.
Publicado: (2021)

Gut Microbiome and Metabonomic Profile Predict Early Remission to Anti-Integrin Therapy in Patients with Moderate to Severe Ulcerative Colitis
por: Liu, Jie, et al.
Publicado: (2023)

Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
por: Jeon, Seong Ran
Publicado: (2017)

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
por: Hibi, Toshifumi, et al.
Publicado: (2019)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

Energy Expenditure in Japanese Patients with Severe or Moderate Ulcerative Colitis
por: Sasaki, Masaya, et al.
Publicado: (2010)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Mitochondria in Ulcerative Colitis
por: Stange, Eduard F.
Publicado: (2021)

Landmark studies and emerging strategies for the management of acute severe ulcerative colitis
por: Weissman, Simcha, et al.
Publicado: (2019)

Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
por: Kim, You Sun
Publicado: (2021)

Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
por: Feagan, Brian G, et al.
Publicado: (2019)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
por: Ben-Horin, Shomron, et al.
Publicado: (2022)

Is once daily multimatrix mesalazine therapy effective regardless of the dose in patients with mild to moderate ulcerative colitis?
por: Jeon, Seong Ran
Publicado: (2018)

Uncovering the cause of ulcerative colitis
por: Roberts‐Thomson, Ian C, et al.
Publicado: (2019)

The Clinical Significance and Risk Factors of Colorectal Stricture in Ulcerative Colitis
por: Park, Sung Chul, et al.
Publicado: (2020)

Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new?
por: Andrew, Rachel E, et al.
Publicado: (2016)

Natural compounds as safe therapeutic options for ulcerative colitis
por: Gupta, Mukta, et al.
Publicado: (2022)

An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
por: Ferretti, Francesca, et al.
Publicado: (2022)

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2013)

Characterization of Stool Virome in Children Newly Diagnosed With Moderate to Severe Ulcerative Colitis
por: Tokarz, Rafal, et al.
Publicado: (2019)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Kassir, Nastya, et al.
Publicado: (2022)

Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
por: Moein, Anita, et al.
Publicado: (2022)

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?
por: Kim, Yoon Jae
Publicado: (2016)

Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea
por: Yoon, Hyuk, et al.
Publicado: (2023)

Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?
por: Lee, Jin Wook, et al.
Publicado: (2021)

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
por: Fenu, Elisabetta, et al.
Publicado: (2022)

Chronic thromboembolic pulmonary hypertension: More options, more awareness
por: Allwood, B W, et al.
Publicado: (2023)

Lymphoplasmacellular mucositis ameliorated by α4β7 integrin inhibitor vedolizumab in a patient with ulcerative colitis
por: Shalabi, Doaa, et al.
Publicado: (2019)

Changes in energy metabolism after induction therapy in patients with severe or moderate ulcerative colitis
por: Inoue, Mai, et al.
Publicado: (2015)

Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis
por: Hu, Jianxia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mncos87c2u4p94cq0bgbm6t53s